---
title: "文件：药明合联持有人寻求通过大宗交易筹集至多 24 亿港元"
description: "交易条款显示，药明合联生物技术有限公司的持有人合全药业香港投资有限公司寻求通过大宗交易筹集至多 24 亿港元资金：发行 3030 万股，每股定价 77 至 79.07 港元，较周三收盘价 82.80 港元折让 4.5% 至 7%，占现有流通股约 2.47%，卖方锁定期 90 天，摩根士丹利担任独家簿记管理人。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260268080.md"
published_at: "2025-10-08T10:26:30.000Z"
---

# 文件：药明合联持有人寻求通过大宗交易筹集至多 24 亿港元

> 交易条款显示，药明合联生物技术有限公司的持有人合全药业香港投资有限公司寻求通过大宗交易筹集至多 24 亿港元资金：发行 3030 万股，每股定价 77 至 79.07 港元，较周三收盘价 82.80 港元折让 4.5% 至 7%，占现有流通股约 2.47%，卖方锁定期 90 天，摩根士丹利担任独家簿记管理人。

交易条款显示，药明合联生物技术有限公司的持有人合全药业香港投资有限公司寻求通过大宗交易筹集至多 24 亿港元资金：发行 3030 万股，每股定价 77 至 79.07 港元，较周三收盘价 82.80 港元折让 4.5% 至 7%，占现有流通股约 2.47%，卖方锁定期 90 天，摩根士丹利担任独家簿记管理人。

### Related Stocks

- [02268.HK - 药明合联](https://longbridge.com/zh-CN/quote/02268.HK.md)
- [MS.US - 摩根士丹利](https://longbridge.com/zh-CN/quote/MS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | Nomura Adjusts WuXi XDC Cayman's Price Target to HK$87.73 From HK$82.72, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/275736820.md) |
| Morgan Stanley Decreases Total Voting Rights in flatexDEGIRO SE to 3.19% | Morgan Stanley has reduced its voting rights in flatexDEGIRO SE from 3.63% to 3.19%, a decrease of 0.44 percentage point | [Link](https://longbridge.com/zh-CN/news/275636914.md) |
| WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM | WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. | [Link](https://longbridge.com/zh-CN/news/275675866.md) |
| J.P. Morgan Appoints Geneva-Based Banker to International Senior Role | J.P. Morgan has appointed Burkhard Koep as the new Global Head of Communications Investment Banking, based in Geneva. Ko | [Link](https://longbridge.com/zh-CN/news/275729531.md) |
| Here's How Much $100 Invested In Morgan Stanley 5 Years Ago Would Be Worth Today | Morgan Stanley (NYSE:MS) has delivered an average annual return of 19.52% over the past 5 years, outperforming the marke | [Link](https://longbridge.com/zh-CN/news/274864800.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
